Dutch biotech enters clinical phase
Nijmegen-based Tagworks has passed the investigational new drug (IND) review by the US Food and Drug Administration (FDA) for its antibody-drug conjugate TGW101. A Phase 1 clinical trial is now being initiated in the US.
Want to read more?
Create a free account today!
- Gain access to all our content on chemistry, life sciences and process technology;
- Get our weekly newsletter so you never miss a story.
As a member of the KNCV, KVCV, NBV, or NVBMB you have unlimited access. Log in here.
